Last $10.75 USD
Change Today -0.68 / -5.95%
Volume 18.3K
AQXP On Other Exchanges
As of 3:59 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/14 - $14.35
52 Week Low
10/13/14 - $5.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical stage pharmaceutical company, discovers and develops oral drug candidates for the treatment of inflammatory diseases and cancer. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its principal product candidate is AQX-1125, a SHIP1 activator, which is in Phase II clinical trials for chronic obstructive pulmonary disease and bladder pain syndrome/interstitial cystitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

22 Employees
Last Reported Date: 11/4/14
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $183.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $270.2K
Compensation as of Fiscal Year 2013.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Initiates Patient Dosing in the Phase 2 Clinical Trial of AQX-1125 in Atopic Dermatitis

Aquinox Pharmaceuticals Inc. announced that it has initiated dosing in a Phase 2 clinical trial of AQX-1125 for the treatment of atopic dermatitis (AD). The KINSHIP clinical trial is being conducted at clinical research centers in Canada as a randomized, double-blind, multicenter, placebo-controlled Phase 2 trial evaluating the efficacy and safety of AQX-1125 in approximately 50 adult patients with mild to moderate AD. The KINSHIP trial's primary endpoint is change from baseline in Total Lesion Symptom Score (TLSS) after 12 weeks of treatment. The TLSS is a comprehensive assessment of AD symptoms where AQX-1125 may have a beneficial effect. Secondary endpoints include safety, pharmacokinetics and additional parameters for assessing AD. The company believes AQX-1125's ease of administration as a once daily, oral, anti-inflammatory medicine, and its ability to reduce immune cell migration to inflamed surfaces, could provide a clinically meaningful benefit to AD patients. The KINSHIP trial has been designed to first evaluate AQX-1125's safety and efficacy in mild to moderate AD patients. The company's eventual interest is AQX-1125's potential as an effective, oral therapy for moderate to severe AD patients. The prevalence of AD ranges from 1%-20% worldwide. An estimated 17.8 million Americans are affected by AD, which is considered underdiagnosed by physicians. Approximately two-thirds of Americans with AD suffer from the moderate to severe form of the disease, where existing therapies are often ineffective or unsuitable for long-term treatment.

Aquinox Pharmaceuticals Inc. Announces Appointment of David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance

Aquinox Pharmaceuticals Inc. announced the appointment of Mr. David C. Mitchell as Vice President of Global Regulatory Affairs & Quality Assurance. Mr. Mitchell will join Aquinox's management team to guide the strategic direction of Aquinox's global regulatory and quality assurance functions. Mr. Mitchell has over 35 years of regulatory experience, including negotiations with United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to facilitate new drug approval. Most recently he led global regulatory strategy at AbbVie Inc. for developmental drug candidates targeting various cancers and immunologic disorders.

Aquinox Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Aquinox Pharmaceuticals Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss before income taxes of $6,284,302 against $3,372,531 a year ago. Net loss was $6,284,080 against $3,367,487 a year ago. The increase in net loss was primarily due to the ongoing advancement of AQX-1125 through the FLAGSHIP and LEADERSHIP trials, and costs associated with operating as a public company. For the nine months, the company reported net loss before income taxes of $15,936,739 against $5,194,300 a year ago. Net loss was $15,936,517 against $5,189,256 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $10.75 USD -0.68

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at